Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-DOS47 with Pemetrexed/Carboplatin in NSCLC
NCT02309892Phase 1Terminated
- Sponsor
- Helix BioPharma
- Start
- Apr 2015
- Primary completion
- Aug 2019
- Modality
- Antibody Fragments, Antibody-Drug Conjugates (ADCs), Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of L-DOS47 in non-small cell lung cancer (NSCLC), sponsored by Helix BioPharma. Primary endpoints: Treatment Emergent Adverse Events at 12 weeks, Dose Limiting Toxicities at 21 days and 1 more. Started Apr 2015; status: terminated.
02
Drugs
L-DOS47
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02309892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02309892.